Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PROCEPT BioRoboticsPRCT -1.50%70 Cash-to-Debt is 2.94 as of Jun. 2026, which is 10% below its 10-year median of 3.25. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $84.01 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 847 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks better than 57.97% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PROCEPT BioRobotics's cash to debt ratio for the quarter that ended in Jun. 2026 was 2.94.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PROCEPT BioRoboticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for PROCEPT BioRobotics's Cash-to-Debt or its related term are showing as below:
PRCT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.81 Med: 3.25 Max: 5.9
Current: 2.94
During the past 7 years, PROCEPT BioRobotics's highest Cash to Debt Ratio was 5.90. The lowest was 1.81. And the median was 3.25.
PRCT's Cash-to-Debt is ranked better than 57.97% of 847
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs PRCT: 2.94
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
PROCEPT BioRobotics Cash-to-Debt Related Terms
PROCEPT BioRobotics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, PROCEPT BioRobotics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (PRCT) has a Cash-to-Debt of 2.94 as of Jun. 2026. This is 10% below median its historical median of 3.25. Over the past decade, PROCEPT BioRobotics' Cash-to-Debt has ranged from 1.81 to 5.90. According to the industry distribution chart, PROCEPT BioRobotics ranks #356 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 42%.
Is PROCEPT BioRobotics' Cash-to-Debt too high?
PROCEPT BioRobotics' current Cash-to-Debt of 2.94 is 10% below median its 10-year median of 3.25. Over the past 10 years, this metric has ranged from a low of 1.81 to a high of 5.90. The Medical Devices & Instruments industry median Cash-to-Debt is 1.68. PROCEPT BioRobotics' value of 2.94 is 75% above this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #356 out of 847 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Cash-to-Debt compare to INMD and LMRI?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #356 out of 847 companies for Cash-to-Debt. This puts PROCEPT BioRobotics in the upper half of its industry. The industry median Cash-to-Debt is 1.68. PROCEPT BioRobotics' value of 2.94 is 75% above this benchmark. Historically, PROCEPT BioRobotics' own Cash-to-Debt has ranged from 1.81 to 5.90 over the past decade. While the company's 10-year median is 3.25 vs. the industry median of 1.68, PROCEPT BioRobotics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.68, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current Cash-to-Debt of 2.94 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current Cash-to-Debt is 2.94, which is 10% below median its own 10-year median of 3.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $84.01, compared to a current price of $21.66 — trading 74.2% below its estimated fair value. The current Cash-to-Debt is 2.94, which is 10% below median its 10-year median of 3.25 and 75% above the Medical Devices & Instruments industry median of 1.68. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Cash-to-Debt is 2.94 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $21.66 is trading 74.2% below its estimated GF Value™ of $84.01.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
Cash-to-Debt: 2.94 (10% below median its 10-year median of 3.25)
GF Value™: $84.01 vs. price of $21.66 (74.2% below fair value)
Industry Position: 75% above the Medical Devices & Instruments median (#356 of 847)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
